Tumor-directed immune activation

Tumor-directed immune activation is a therapeutic strategy rather than a single molecular target. It encompasses various approaches designed to stimulate the host's immune system specifically within the tumor microenvironment (TME) to identify and destroy cancer cells [PMID: 33024326]. This is often achieved through the use of bispecific antibodies, chimeric antigen receptor (CAR) T-cells, or tumor-targeted cytokines that bridge immune effector cells, such as T-cells or NK cells, to tumor-associated antigens [PMID: 30610225]. By localizing the immune response, these therapies aim to enhance anti-tumor efficacy while reducing the systemic side effects typically associated with non-specific immune stimulation [PMID: 24419461]. Common molecular targets involved in this process include CD3 on T-cells and various tumor-specific markers such as CD19, BCMA, or HER2 [PMID: 29158371]. However, the potent activation of immune cells can lead to significant safety concerns, most notably cytokine release syndrome (CRS) and neurotoxicity [PMID: 30033249].

Other names

Tumor-targeted immunotherapyLocalized immune activationIntratumoral immune activationTargeted immune stimulation

Selective stimulation of the immune system within the tumor microenvironment to recognize and eliminate malignant cells, typically achieved by bridging immune effector cells to tumor-associated antigens or delivering immunostimulatory agents directly to the tumor site.